Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test

Andrea Di Matteo,Andrea Di Matteo,Kulveer Mankia,Kulveer Mankia,Leticia Garcia-Montoya,Leticia Garcia-Montoya,Sana Sharrack,Laurence Duquenne,Laurence Duquenne,Jacqueline L Nam,Michael Mahler,Paul Emery,Paul Emery

doi:10.1136/rmdopen-2023-003927

Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test

Andrea Di Matteo, Andrea Di Matteo + Show 11 more

Open Access

https://doi.org/10.1136/rmdopen-2023-003927

Copy DOI

Journal: RMD Open	Publication Date: Apr 1, 2024
License type: CC BY-NC 4.0

Affiliation: Sheffield Teaching Hospitals NHS Foundation Trust

#Diagnosis Of Rheumatoid Arthritis #OR For Progression + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectivesTo investigate the role of third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in predicting progression to inflammatory arthritis (IA) in individuals with new musculoskeletal (MSK) symptoms and a negative second-generation anti-CCP...

Full Text